42 -6 (56) 2023 — Boboerova Dildora Nabizhanovna — COMORBID PATIENT WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH CORONARY ARTERY DISEASE AND HYPERTENSION

COMORBID PATIENT WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH CORONARY ARTERY DISEASE AND HYPERTENSION

Boboerova Dildora Nabizhanovna Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

A comorbid patient with the chronic obstructive pulmonary disease (COPD) in combination with cardiovascular diseases (CHD) has a poor prognosis due to the early progression of the pulmonary hypertension (PH). The study surveyed an opportunity of the PH detection using an active PH verification strategy in outpatients with COPD and stable angina pectoris. Goal. A comorbid patient with the chronic obstructive pulmonary disease (COPD) in combination with cardiovascular diseases (CHD) has a poor prognosis due to the early progression of the pulmonary hypertension (PH). The study surveyed an opportunity of the PH detection using an active PH verification strategy in outpatients with COPD and stable angina pectoris.

Keywords: chronic obstructive pulmonary disease, angina pectoris, arterial hypertension, comorbidity, pulmonary hypertension

First page

256

Last page

259

For citation: Boboerova Dildora Nabizhanovna – COMORBID PATIENT WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH CORONARY ARTERY DISEASE AND HYPERTENSION //New Day in Medicine 2023 6(56): 256-259 https://newdaymedicine.com/index.php/2023/06/20/l-209/

LIST OF REFERENCES:

1. Global Strategy for diagnosis, management and prevention of COPD. Scientific information and recommendations for COPD programs. Updated (2013) http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013Feb13.pdf
2. Engstrom G, Lind P, Hedblad B, et al. Lung function and cardiovascular risk. Circulation. (2002) 106(20):2555-60.
3. Sin D.D., Wu L., Man S.F. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. (2005) 127(6):1952-9. https:// doi:10.1378/chest.127.6.1952
4. Sin D.D., Anthonisen N.R., Soriano J.B., Agusti A.G. Mortality in COPD: role of comorbidities. Eur Respir J. (2006) 28(6):1245-57. https://doi:10.1183/09031936.00133805
5. Macnee W, Maclay J, McAllister D. Cardiovascular injury and repair in chronic obstructive pulmonary disease. Proc Am Thorac Soc. (2008) 5(8):824-33. https://doi:10.1513/pats.200807-071TH
6. Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. (2013) 1(1):73-83. https://doi:10.1016/S2213-2600(12)70060-7
7. Pływaczewski R., Maciejewski J., Bednarek M., Zieliński J. et al. Causes of deaths in COPD patients in primary care setting – a 6-year followup. Pneumonol Alergol Pol. (2015) 83(3):193-202. https://doi:10.5603/ PiAP.2015.0031
8. Curkendall S.M, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada: cardiovascular disease in COPD patients. Ann Epidemiol. (2006) 16(1):63-70. https://doi:10.1016/j.annepidem.2005.04.008
9. Sabit R, Thomas P, Shale DJ, et al. The effects of hypoxia on markers of coagulation and systemic inflammation in patients with COPD. Chest. (2010) 138(1):47-51. https://doi:10.1378/chest.09-2764
10. MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. (2005) 2(1):50-60. https://doi: 10.1513
11. Чазова И.Е., Чучалин А.Г., Зыков К.А., Ратова Л.Г. Диагностика и лечение пациентов с артериальной гипертонией и хронической обструктивной болезнью легких (рекомендации Российского медицинского общества по артериальной гипертонии и Российского респираторного общества). Системные гипертензии. (2013) 10(1):5-34.
12. Григорьева Н.Ю. Коморбидный пациент с АГ и ХОБЛ. Лечащий врач. (2016) 7:24-27.
13. Mortensen E.M., Copeland L.A., Pugh M.J., Restrepo M.I., de Molina R.M., Nakashima B. et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. – (2009) 10:45.